SCHEMBL200592

SCHEMBL200592

O=C(Cc1ccccc1)SSC(=O)Cc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAM P19021 2/20 0.63
CES1 P23141 2/20 0.61
CES2 O00748 1/20 0.61
AKR1B1 P15121 1/20 0.61
L3MBTL1 Q9Y468 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
HDAC8 Q9BY41 2/20 0.52
HDAC6 Q9UBN7 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
FNTA P49354 1/20 0.50
FNTB P49356 1/20 0.50
MAPK1 P28482 2/20 0.48
ALDH1A1 P00352 1/20 0.48
CTBP2 P56545 1/20 0.48
EPHX2 P34913 1/20 0.48
GAA P10253 2/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 2/20 0.46
ABCC4 O15439 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL905745 0.89 PAM (0.53) PAMCES1CES2AKR1B1L3MBTL1
SCHEMBL23258762 0.88 PAM (0.52) PAMCES1CES2AKR1B1L3MBTL1
SCHEMBL15574257 0.85 PAM (0.63) PAMCES1CES2AKR1B1L3MBTL1
SCHEMBL27546894 0.83 PAM (0.61) PAMCES1CES2AKR1B1L3MBTL1
SCHEMBL27988220 0.82 PAM (0.66) PAMCES1CES2AKR1B1L3MBTL1
SCHEMBL7324963 0.81 PAM (0.59) PAMCES1CES2AKR1B1L3MBTL1
SCHEMBL200593 0.81 PAM (0.59) PAMCES1CES2AKR1B1L3MBTL1
SCHEMBL3048336 0.79 TDP1 (0.79) PAMCES1CES2AKR1B1L3MBTL1
SCHEMBL28222699 0.79 PAM (0.57) PAMCES1CES2AKR1B1L3MBTL1
SCHEMBL28874611 0.79 PAM (0.57) PAMCES1CES2AKR1B1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1525 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4725950-A1 IMPROVED SOLID-PHASE PHOSPHORAMIDITE-SYNTHESIS OF LONG OLIGONUCLEOTIDE MOLECULES BioSpring Gesellschaft für Biotechnologie mbH (DE) 2026-04-15 EP claimed
EP-4725949-A1 IMPROVED SOLID-PHASE PHOSPHORAMIDITE-SYNTHESIS OF LONG OLIGONUCLEOTIDE MOLECULES BioSpring Gesellschaft für Biotechnologie mbH (DE) 2026-04-15 EP claimed
US-20260097383-A1 SOLID-PHASE PHOSPHORAMIDITE-SYNTHESIS OF LONG OLIGONUCLEOTIDE MOLECULES BioSpring Gesellschaft für Biotechnologie mbH (DE) 2026-04-09 US claimed
US-12492220-B2 Method for the preparation of oligonucleotides THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2025-12-09 US claimed
US-12435105-B2 Technologies for oligonucleotide preparation WAVE LIFE SCIENCES LTD. (SG) 2025-10-07 US claimed
US-12264174-B2 Process for preparing imetelstat GERON CORPORATION (US) 2025-04-01 US claimed
EP-4526944-A1 THTOCARBONATE COMPOSITIONS FOR LITHIUM- SULFUR BATTERIES Conamix Inc. (US) 2025-03-26 EP claimed
CN-113631564-B Method for producing oligonucleotide having phosphorothioate site 味之素株式会社 2025-02-25 CN claimed
CN-114573652-B Process for synthesizing medicinal nucleic acid 安徽瑞拜药业有限公司 2025-02-07 CN claimed
EP-3475292-B1 SYNTHESIS OF THIOLATED OLIGONUCLEOTIDES WITHOUT A CAPPING STEP BIOGEN MA INC (US) 2024-09-18 EP claimed
EP-1386925-A1 Method for preparing oligonucleotides Girindus AG (DE) 2004-02-04 EP claimed
US-20030212267-A1 Synthesis of sulfurized oligonucleotides IONIS PHARMACEUTICALS, INC. 2003-11-13 US claimed
EP-1246833-A4 IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS INC (US) 2003-04-09 EP claimed
EP-1246833-A1 IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2002-10-09 EP claimed
WO-2001051502-A1 IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2001-07-19 WO claimed
US-6242591-B1 Synthesis of sulfurized 2'-substituted oligonucleotides ISIS PHARMACEUTICALS, INC. 2001-06-05 US claimed
EP-1023310-A4 IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS INC (US) 2001-05-16 EP claimed
US-6114519-A PHOSPHITYLATION; OXIDATION ACYL DISULFIDE ISIS PHARMACEUTICALS, INC. (US) 2000-09-05 US claimed
EP-1023310-A1 IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2000-08-02 EP claimed
WO-1999019340-A1 IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 1999-04-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097383-A1 SOLID-PHASE PHOSPHORAMIDITE-SYNTHESIS OF LONG OLIGONUCLEOTIDE MOLECULES RNGTT, NSUN2, RNMT PAM 1193/4885CES1 3414/4885CES2 3863/4885
US-12435105-B2 Technologies for oligonucleotide preparation POLRMT, DCLRE1B, RNGTT PAM 2030/4885CES1 2271/4885CES2 4249/4885
US-12492220-B2 Method for the preparation of oligonucleotides POLN, POLRMT, POLI PAM 2284/4885CES1 4524/4885CES2 4455/4885
US-12264174-B2 Process for preparing imetelstat TERT, RNGTT, TRMT1L PAM 1297/4885CES1 2380/4885CES2 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.